---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-001828"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2022-02-18T23:59:59+00:00"
generated_at: "2026-06-27T06:28:50.813002+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO

## Summary
- Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.
- Annual base salary of $325,000; target bonus up to 40% of base salary.
- Stock award of 25,000 shares and option to purchase 175,000 shares vesting over 3 years.
- Options fully accelerate upon a change of control; employment agreement to be signed.
- Ohri is a CPA with prior CFO experience at ToughBuilt Industries and Big 4 background.

## SEC filing metadata
- accession: 0001654954-22-001828
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2022-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/gtbp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-001828
- JSON: https://secwatch.observer/filing/0001654954-22-001828.json
- Plain text: https://secwatch.observer/filing/0001654954-22-001828.txt

## Key facts
- Executive change
  Manu Ohri was appointed as Chief Financial Officer at GT Biopharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective February 14, 2022, the Registrant appointed Manu Ohri as the Registrant’s Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm
- Executive change
  Gavin Choy departed as Acting Chief Financial Officer at GT Biopharma, Inc..
  - Action: ceased serving
  - Role: Acting Chief Financial Officer
  source text: Gavin Choy ceased serving as the Registrant’s Acting Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.